Educational Notice
This article is written for researchers, clinicians, and informed adults seeking to understand the scientific literature on liraglutide. It is not medical advice, a treatment recommendation, or an endorsement of any specific use. Liraglutide (Victoza, Saxenda) is an FDA-approved prescription medication. It should only be obtained and used under the supervision of a licensed healthcare provider. Consult a qualified healthcare professional before making any health or treatment decisions.
BLUF: Bottom Line Up Front
Liraglutide is an FDA-approved drug available under two brand names: Saxenda (for weight loss) and Victoza (for diabetes). It works by mimicking GLP-1, a hormone that controls appetite. It has a proven track record—thousands of people have used it for years, so side effects and benefits are well-known. It’s less powerful than newer competitors like semaglutide, but the safety data is rock solid. This is the established, tried-and-tested option.
The GLP-1 pioneer that proved daily injectable weight loss drugs could work — now overshadowed by its weekly successors
Liraglutide was the compound that proved GLP-1 receptor agonism could produce clinically meaningful weight loss in a large, well-controlled Phase III trial — before semaglutide made that question seem obvious in retrospect. Novo Nordisk’s SCALE trial program, published from 2014 to 2017, established liraglutide 3 mg daily as the first GLP-1 agonist approved specifically for obesity (Saxenda, 2014) and demonstrated that the ~8% weight loss produced in SCALE Obesity was sufficient to improve a range of cardiometabolic risk factors. LEADER, the cardiovascular outcomes trial in type 2 diabetes, documented the class CV benefit in 2016.
In 2026, liraglutide is a first-generation GLP-1 agonist that has been substantially superseded for weight loss by semaglutide (more weight loss, once weekly vs. once daily) and tirzepatide (greatest weight loss, once weekly). STEP 8 directly compared the two Novo Nordisk GLP-1 agonists and semaglutide produced more than twice the weight loss of liraglutide. Liraglutide remains clinically relevant — it has the longest post-approval safety track record of any injectable GLP-1 agonist, pediatric approval that semaglutide only recently matched, and established use in patients who cannot tolerate semaglutide or tirzepatide.
Table of Contents
- What Is Liraglutide?
- Origins and Regulatory History
- Mechanism of Action
- Approved Indications
- Key Research Areas and Studies
- Common Claims versus Current Evidence
- Safety, Risks, and Limitations
- Regulatory Status
- Approved Clinical Dosing
- Frequently Asked Questions
- Related Compounds: How Liraglutide Compares
- Summary and Key Takeaways
- Selected References
- Further Reading
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyQuick Facts
| Type | Synthetic GLP-1 receptor agonist — first once-daily injectable GLP-1 agonist |
| Brand names | Victoza (T2D, 1.2–1.8 mg SC daily); Saxenda (obesity, 3 mg SC daily) |
| Molecular weight | 3751.2 Da |
| Target receptor | GLP-1R |
| Mechanism | GLP-1R agonist via C16 fatty acid albumin binding — same class mechanism as semaglutide but shorter half-life |
| Half-life | ~13 hours — requires once-daily dosing |
| Route | Subcutaneous injection (once daily) |
| Developer | Novo Nordisk |
| FDA approval | Victoza: 2010 (T2D); Saxenda: 2014 (obesity); pediatric obesity approval: 2020 |
| WADA status | Not prohibited |
| Evidence tier | Approved Drug — multiple Phase III RCTs across indications |
| Context | Preceded semaglutide; less weight loss efficacy but well-established safety profile; still first-line in some settings |
What Is Liraglutide?
Liraglutide is a GLP-1 analog with 97% sequence homology to native human GLP-1. The key structural modification is a C16 fatty acid chain attached via a glutamic acid linker to Lys26, enabling non-covalent albumin binding. This extends the half-life from native GLP-1’s 2 minutes to approximately 13 hours — long enough for once-daily dosing. The mechanism of action at GLP-1R is identical to semaglutide: glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite suppression via hypothalamic and brainstem GLP-1R.
Plain English
A single fatty acid chain attached to the peptide lets it grab onto albumin in the blood, stretching its life from 2 minutes to 13 hours. That’s the engineering trick that made daily dosing possible—the same concept semaglutide later improved to achieve weekly dosing.
Liraglutide was Novo Nordisk’s proof-of-concept that fatty acid albumin binding could transform a pharmacokinetically impractical peptide into a once-daily injectable. Semaglutide extended this concept with a longer fatty acid chain and improved linker chemistry to achieve a 7-day half-life. The structural iteration from liraglutide to semaglutide is pharmacologically instructive: the clinical superiority of semaglutide derives substantially from the ability to maintain higher steady-state plasma concentrations with weekly rather than daily dosing, enabling more sustained GLP-1R agonism at relevant tissues.
Origins and Regulatory History
Liraglutide was developed by Novo Nordisk and received FDA approval for type 2 diabetes (Victoza) in January 2010 — the first once-daily GLP-1 agonist to reach the US market. Saxenda (liraglutide 3 mg for obesity) was approved in December 2014, making it the first GLP-1 agonist approved specifically for weight management in adults. Pediatric approval for Saxenda in adolescents ≥12 years with obesity followed in 2020. LEADER (cardiovascular outcomes trial) published in 2016, establishing the CV benefit of liraglutide in high-CV-risk T2D patients.
Mechanism of Action
Liraglutide’s GLP-1R mechanism is the same class mechanism shared by all GLP-1R agonists: Gs-coupled adenylyl cyclase activation, cAMP elevation, glucose-dependent insulin secretion from pancreatic beta cells, glucagon suppression from alpha cells, gastric emptying delay via vagal pathways, and central appetite suppression via hypothalamic and brainstem GLP-1R. The key pharmacokinetic feature is the 13-hour half-life from albumin binding, which requires daily dosing to maintain therapeutic plasma concentrations.
Plain English
Liraglutide works through the exact same GLP-1 receptor mechanism as semaglutide—boosting insulin when blood sugar is high, suppressing glucagon, slowing stomach emptying, and reducing appetite in the brain. The difference is duration: liraglutide lasts 13 hours (daily injection) versus semaglutide’s 7 days (weekly injection).
The difference between 1.8 mg (Victoza diabetes dose) and 3 mg (Saxenda obesity dose) is meaningful: the 3 mg dose produces greater GLP-1R saturation at hypothalamic appetite-regulatory sites, driving the additional weight loss seen with Saxenda that is not observed with Victoza dosing. The dose-response relationship for GLP-1R-mediated appetite suppression is steeper in the hypothalamus than for pancreatic insulin secretion, which is why the obesity dose requires 67% more drug than the diabetes dose.
Plain English
The diabetes dose (1.8 mg) and the weight loss dose (3 mg) aren’t interchangeable. The higher dose pushes more GLP-1R activation in the brain’s appetite centers—that extra central effect is what produces the weight loss, not just better blood sugar control.
Approved Indications
| Indication | Brand | Year | Key Trial | Notes |
|---|---|---|---|---|
| Type 2 diabetes | Victoza 1.2–1.8 mg SC daily | 2010 | LEADER (CV outcomes), LIRAGLUTIDE effect and action in diabetes (LEAD) series | First once-daily GLP-1 agonist; CV risk reduction labeling from LEADER |
| Obesity/overweight with comorbidity (adults) | Saxenda 3 mg SC daily | 2014 | SCALE Obesity and Prediabetes | First GLP-1 agonist approved specifically for obesity |
| Obesity (adolescents ≥12 years) | Saxenda 3 mg SC daily | 2020 | SCALE Teens | First GLP-1 agonist with pediatric obesity approval in the US |
| Reduction of major CV events in T2D | Victoza | 2017 (label update) | LEADER | 13% MACE reduction vs. placebo |
Key Research Areas and Studies
SCALE Program
SCALE Obesity and Prediabetes (N=3731): liraglutide 3 mg SC daily produced 8.0% mean weight loss at 56 weeks vs. 2.6% placebo. 63% of participants achieved ≥5% weight loss vs. 27% placebo. Improvements in waist circumference, blood pressure, and prediabetes conversion rates documented. SCALE Maintenance showed weight regain on discontinuation. SCALE Diabetes (in T2D): 6.0% weight loss vs. 2.0% placebo.
LEADER — Cardiovascular
N=9340, T2D adults with high CV risk. Liraglutide reduced 3-point MACE by 13% (HR 0.87), CV death by 22% (HR 0.78), and all-cause death by 15% (HR 0.85) over median 3.8 years. LEADER established the GLP-1 class cardiovascular benefit before the SUSTAIN-6 or SELECT semaglutide data.
STEP 8 — Head-to-Head vs. Semaglutide
N=338, adults with obesity. Semaglutide 2.4 mg weekly produced 15.8% weight loss vs. 6.4% for liraglutide 3 mg daily at 68 weeks. More than twice the weight loss with a less frequent injection. STEP 8 definitively established semaglutide’s superiority for weight management.
Common Claims versus Current Evidence
| Claim | Evidence | Verdict |
|---|---|---|
| Liraglutide produces meaningful weight loss | SCALE Obesity trial (N=3731): liraglutide 3 mg SC daily produced mean 8.0% body weight loss at 56 weeks vs. 2.6% placebo. This is less than semaglutide (~15%) or tirzepatide (~22%) but represents the first Phase III obesity pharmacotherapy to significantly exceed placebo in the modern era. | Phase III Supported |
| Liraglutide 1.8 mg (Victoza) produces significant weight loss | Victoza dosed for diabetes (1.8 mg) produces ~3–4% weight loss in T2D trials — meaningful but modest. The obesity dose (3 mg Saxenda) is required for significant weight loss. | Dose-Dependent — Modest |
| Liraglutide reduces cardiovascular events | LEADER trial (N=9340, T2D patients with high CV risk): liraglutide reduced 3-point MACE by 13% vs. placebo (HR 0.87, 95% CI 0.78–0.97). CV death reduced by 22%. This established the cardiovascular benefit of the GLP-1 agonist class before semaglutide SELECT data. | Phase III Supported |
| Liraglutide is equivalent to semaglutide | Liraglutide produces less weight loss (~8% vs ~15%), requires daily vs. weekly injection, and has lower adherence in practice. Head-to-head STEP 8 trial (N=338): semaglutide 2.4 mg weekly produced 15.8% weight loss vs. 6.4% for liraglutide 3 mg daily. | False |
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklySafety, Risks, and Limitations
Liraglutide’s safety profile is the most extensively documented in the GLP-1 class by virtue of its decade-plus post-approval history. GI adverse effects (nausea, vomiting, diarrhea, constipation) follow the class pattern and are most pronounced during dose escalation. The class warnings — pancreatitis, thyroid C-cell tumors, gallbladder disease — apply to liraglutide as to all GLP-1R agonists. The LEADER trial in 9,340 patients over nearly 4 years provides substantial long-term safety data that newer agents in the class lack. Injection site reactions are common with daily SC injection. Daily injection burden is the most significant tolerability disadvantage relative to once-weekly agents.
Regulatory Status
Liraglutide is a prescription medication in the United States and all major jurisdictions. It is not WADA prohibited. Generic competition from biosimilars is beginning to emerge, with implications for access and pricing. Novo Nordisk’s strategic pivot toward semaglutide and tirzepatide competition has reduced commercial focus on liraglutide; prescribing patterns reflect this shift.
Approved Clinical Dosing
| Indication | Starting Dose | Titration | Maintenance | Route | Frequency |
|---|---|---|---|---|---|
| Type 2 Diabetes (Victoza) | 0.6 mg/day | 0.6 mg × 1 wk → 1.2 mg → 1.8 mg if needed | 1.2–1.8 mg | SC injection | Once daily |
| Obesity ≥BMI 30 or ≥27 with comorbidity (Saxenda) | 0.6 mg/day | Weekly escalation: 0.6→1.2→1.8→2.4→3.0 mg | 3.0 mg | SC injection | Once daily |
| Pediatric obesity ≥12 years (Saxenda) | 0.6 mg/day | Same weekly escalation | 3.0 mg (or max tolerated) | SC injection | Once daily |
Frequently Asked Questions
Is Saxenda still worth using when semaglutide and tirzepatide are available?
Saxenda remains a viable option in specific circumstances: for patients who cannot tolerate semaglutide (which is uncommon but occurs), in pediatric obesity (where semaglutide adolescent data is more recent and tirzepatide pediatric data is pending), and in settings where biosimilar or lower-cost liraglutide becomes available before semaglutide biosimilars. For most adult patients with obesity, the superior weight loss and less frequent injection of semaglutide or tirzepatide makes them the preferred agents where access is available.
Is there a liraglutide biosimilar?
Biosimilar liraglutide development is in progress in multiple markets. US patent landscape for liraglutide extends into the mid-2020s in some formulations. Verify current biosimilar availability with prescribers or pharmacists, as this market is evolving rapidly.
Related Compounds
| Compound | Target(s) | Class | Route | Weight Loss Data | Status | WADA |
|---|---|---|---|---|---|---|
| Semaglutide | GLP-1R | GLP-1 agonist | SC weekly / oral | ~15% body weight | Approved (Ozempic/Wegovy) | Not prohibited |
| Tirzepatide | GLP-1R + GIPR | Dual GLP-1/GIP | SC weekly | ~22% body weight | Approved (Mounjaro/Zepbound) | Not prohibited |
| Liraglutide | GLP-1R | GLP-1 agonist | SC daily | ~5–8% body weight | Approved (Victoza/Saxenda) | Not prohibited |
| Retatrutide | GLP-1R+GIPR+GCGR | Triple agonist | SC weekly | ~24% (Phase II) | Phase III (TRIUMPH) | Not prohibited |
| CagriSema | GLP-1R+AMY1-3 | GLP-1 + amylin | SC weekly | ~22.7% (REDEFINE 1) | Phase III (REDEFINE) | Not prohibited |
| Orforglipron | GLP-1R | Non-peptide oral | Oral daily | ~14.7% (Phase III) | Phase III (ATTAIN) | Not prohibited |
| Survodutide | GLP-1R+GCGR | GLP-1/glucagon | SC weekly | ~18.7% (Phase II) | Phase II/III | Not prohibited |
| 5-Amino-1MQ | NNMT inhibition | NNMT inhibitor | Oral (research) | Animal models only | Preclinical | Not prohibited |
| Compound | Type | Primary Target | Half-Life | FDA Status | WADA Status | Evidence Tier | Weight Loss Efficacy | Route | Mechanism Class | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|
| Semaglutide | Synthetic GLP-1 receptor agonist peptide | GLP-1R | ~7 days | FDA-approved (Wegovy, Ozempic) | Prohibited — S4 (Class 2 Hormone/Analogs) | Tier 1 — Approved Drug | Up to 22% body weight reduction (Phase III) | Subcutaneous injection (weekly) | GLP-1 agonist | Longest half-life in class; once-weekly dosing. Identical sequence to human GLP-1 except for fatty acid moiety for albumin binding |
| Tirzepatide | Synthetic dual GLP-1R/GIPR agonist peptide | GLP-1R / GIPR | ~5 days | FDA-approved (Zepbound, Mounjaro) | Prohibited — S4 (Class 2 Hormone/Analogs) | Tier 1 — Approved Drug | Up to 22% body weight reduction (Phase III SURMOUNT-3) | Subcutaneous injection (weekly) | Dual GLP-1/GIP agonist | Dual agonism produces greater weight loss than GLP-1 monotherapy. Glucose-dependent mechanism |
| Retatrutide | Synthetic triple GLP-1R/GIPR/GcgR agonist peptide | GLP-1R / GIPR / GcgR | ~5 days | Phase III clinical trials (not yet approved) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase III) | Up to 24% body weight reduction (Phase II) | Subcutaneous injection (weekly) | Triple GLP-1/GIP/glucagon agonist | Broadest receptor coverage in development. Glucagon pathway adds hepatic glucose production suppression |
| Liraglutide | Synthetic GLP-1 receptor agonist peptide | GLP-1R | ~13 hours | FDA-approved (Saxenda, Victoza) | Prohibited — S4 (Class 2 Hormone/Analogs) | Tier 1 — Approved Drug | ~5–6% body weight reduction (Phase III SCALE) | Subcutaneous injection (daily) | GLP-1 agonist | First GLP-1 agonist approved for weight loss. Daily dosing; shorter half-life than semaglutide |
| Orforglipron | Synthetic selective GLP-1 receptor agonist peptide | GLP-1R | ~11 hours | Phase II clinical trials (pending) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase II) | Up to 15% body weight reduction (Phase II interim) | Oral (non-peptide-like oral bioavailability) | GLP-1 agonist (oral) | Oral formulation in development. If approved, would offer first oral GLP-1 class agent for weight loss |
| CagriSema | Synthetic fixed-ratio triple agonist (GLP-1/GIP/GcgR + amylin) | GLP-1R / GIPR / AmylinR / GcgR | ~5 days (tirzepatide component) | Phase II clinical trials (pending) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase II) | Up to 20% body weight reduction (Phase II interim) | Subcutaneous injection (weekly) | Quadruple agonist (GLP-1/GIP/amylin/glucagon) | Broadest receptor profile in development. Amylin pathway targets satiety and gastric emptying synergistically |
| Survodutide | Synthetic dual GLP-1R/GcgR agonist peptide | GLP-1R / GcgR | ~3–4 days | Phase II clinical trials (pending) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase II) | Up to 18% body weight reduction (Phase II interim) | Subcutaneous injection (weekly) | GLP-1/glucagon dual agonist | Glucagon pathway without GIP agonism. May offer weight loss with reduced nausea vs. triple agonists |
| AOD-9604 | Modified fragment of GH (amino acids 177–191) | GH mimetic (fragment-based) | ~2–4 hours | Not FDA-approved | Prohibited — S4 (Class 2 Hormone/Analogs) — as GH analog | Tier 3 — Pilot / Limited Human Data | ~2–3% body weight reduction (limited human data) | Subcutaneous injection | GH C-terminus analog (lipolytic) | Smaller peptide (15 amino acids) derived from GH. Lipolytic effect without GH-typical muscle anabolism claims |
| 5-Amino-1MQ | Synthetic small molecule quinone metabolite analog | NNMT inhibitor | ~6–8 hours | Not FDA-approved | Not WADA-listed — emerging research compound | Tier 4 — Preclinical Only | ~5–8% body weight reduction (mouse models only; limited human data) | Oral (small molecule) | NNMT inhibition (NAD+ pathway) | Non-peptide. Targets mitochondrial NAD+ metabolism. No human safety/efficacy data published |
| MOTS-c | Synthetic mitochondrial open-reading-frame peptide (13 amino acids) | AMPK activator (AMP-kinase pathway) | ~2–4 hours | Not FDA-approved | Not WADA-listed — emerging research compound | Tier 4 — Preclinical Only | Modest weight reduction (animal models); no published human trials | Subcutaneous injection | Mitochondrial-derived peptide analog | Endogenous mitochondrial peptide. Activates AMPK/SIRT pathway. Only mouse models published |
| Tesamorelin | Synthetic GHRH analog (1-44 amino acids, GHRH-analogue with acyl modification) | GHRH-R | ~26 minutes | FDA-approved (Egrifta for lipodystrophy in HIV) | Prohibited — S2 (GHRH analog) | Tier 1 — Approved Drug | ~2–4% visceral fat reduction (HIV lipodystrophy indication) | Subcutaneous injection (daily) | GHRH analog | Only GH secretagogue approved by FDA for visceral adiposity. Raises GH indirectly via pituitary. Limited weight loss data in non-HIV populations |
Summary
- Liraglutide was the first once-daily injectable GLP-1 agonist and the first GLP-1 agonist approved specifically for obesity — foundational in establishing the GLP-1 agonist class for obesity pharmacotherapy.
- SCALE Obesity: ~8% mean weight loss at 56 weeks. LEADER: 13% MACE reduction in high-CV-risk T2D. Both are Phase III findings.
- Substantially superseded by semaglutide for weight loss (STEP 8: 15.8% vs. 6.4% at 68 weeks) and by tirzepatide for both weight loss and efficacy.
- The most extensive post-approval safety record in the injectable GLP-1 class. Decade-plus of real-world safety data.
- Not WADA prohibited. Prescription medication in all jurisdictions.
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklySelected References
- Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. (SCALE Obesity)
- Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. (LEADER)
- Rubino DM, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity. JAMA. 2022;327(2):138–50. (STEP 8)
- Victoza and Saxenda prescribing information. Novo Nordisk. 2024.
Further Reading
- Semaglutide article — peptidings.com/peptides/semaglutide/
- Weight Loss & Metabolic Cluster Hub — peptidings.com/peptides/weight-loss-metabolic/
Disclaimer
This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations.
Liraglutide (Victoza, Saxenda) is a prescription medication in the United States and most jurisdictions. It should only be obtained and used under the supervision of a licensed healthcare provider.
All citations link to primary sources where available. Evidence limitations are stated explicitly and not minimized.